Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 12, Issue 554, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aaz3339
Keywords
-
Categories
Funding
- NIH SPORE in lymphoma [5P50CA126752]
- Leukemia and Lymphoma Society SCOR award
- Leukemia Lymphoma Society/Rising Tide Foundation
- ASH Scholar Award
- Leukemia Texas Research grant
- ASBMT New Investigator Award
- Edward P. Evans Foundation MDS Discovery Research Grant
- NIH [S10OD018033, S10OD023469, S10OD025240, P30EY002520]
- NATIONAL EYE INSTITUTE [P30EY002520] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Multiple myeloma (MM) is an almost always incurable malignancy of plasma cells. Despite the advent of new therapies, most patients eventually relapse or become treatment-refractory. Consequently, therapies with nonoverlapping mechanisms of action that are nontoxic and provide long-term benefit to patients with MM are greatly needed. To this end, we clinically tested an autologous multitumor-associated antigen (mTAA)-specific T cell product for the treatment of patients with high-risk, relapsed or refractory MM. In this study, we expanded polyclonal T cells from 23 patients with MM. T cells whose native T cell receptors were reactive toward five myeloma-expressed target TAAs (PRAME, SSX2, MAGEA4, Survivin, and NY-ESO-1) were enriched ex vivo. To date, we have administered escalating doses of these nonengineered mTAA-specific T cells (0.5 x 10(7) to 2 x 10(7) cells/m(2)) to 21 patients with MM, 9 of whom were at high risk of relapse after a median of 3 lines of prior therapy and 12 with active, relapsed or refractory disease after a median of 3.5 prior lines. The cells were well tolerated, with only two transient, grade III infusion-related adverse events. Furthermore, patients with active relapsed or refractory myeloma enjoyed a longer than expected progression-free survival and responders included three patients who achieved objective responses concomitant with detection of functional TAA-reactive T cell clonotypes derived from the infused mTAA product.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available